Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Downloads

Investor Inquiries

Press Releases

Press Releases

  • Jun 14, 2022
    Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
    CAMBRIDGE, Mass. , June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the “Offering”)
  • May 25, 2022
    Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
    CAMBRIDGE, Mass. , May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive
  • May 10, 2022
    Wave Life Sciences to Present at Upcoming Investor Conferences
    CAMBRIDGE, Mass. , May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive